Skip to content
Search

Latest Stories

India to soon make available 10m Covid-19 vaccine doses per day

India to soon make available 10m Covid-19 vaccine doses per day

INDIA could have as many as 10 million doses of Covid-19 vaccines available per day in July and August, compared with just under three million now, the government said, trying to allay concerns about shortages and mishandling of the programme.

The world's second most populous country has suffered a disastrous outbreak of infections since April that is only now abating and health experts say the only way it can avert another surge is mass vaccination of its 1.3 billion people.


India on Wednesday (2) reported a daily rise in new coronavirus infections of 132,788 cases over the past 24 hours, while deaths rose by 3,207.

"We don’t doubt that we will be able to increase the pace of vaccinations, once supply is ramped up," government advisor V K Paul told reporters.

Vaccine manufacturers such as Serum Institute of India and Bharat Biotech are scrambling to boost supplies, with the country is also in talks with major foreign vaccine producers such as Pfizer Inc, officials have said.

The health ministry said nearly 45 million people had been fully vaccinated - 4.7 per cent of the country's 950 million adult population. India administered nearly 2.8 million doses on Monday, according to data from its official vaccine portal.

Prime Minister Narendra Modi's government has drawn criticism for a slow vaccine rollout even though India is one of the world's biggest manufacturers of doses, including AstraZeneca's shot.

Several states have complained of a shortage of the AstraZenca vaccines and another called Covaxin, developed by Indian firm Bharat Biotech.

Last month, the government ordered that the interval between two doses of AstraZeneca be increased to 12-16 weeks from 4-6 weeks, which experts said was because of tight supplies.

Paul said there was no plan to mix doses of different vaccines that some officials had suggested earlier. He also said everyone was recommended to take the full two doses of AstraZeneca's vaccine and not limit themselves to one shot.

"India's Covishield schedule is of two doses... there is no change, and Covaxin is also for two doses," Paul said.

Balram Bhargava, head of the Indian Council of Medical Research, said: "Containment has worked. However, it is not a sustainable solution and we have to find a measure to ease the lockdowns."

The South Asian nation's tally of infections now stands at 28.3 million, while the death toll has reached 335,102, health ministry data showed.

More For You

Prada 2026 sandals

Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear

Instagram/prada/iStock

Prada finally acknowledges Kolhapuri chappals inspired 2026 sandals after Indian backlash over Milan show

Quick highlights:

• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy
• Indian artisans and officials accused the brand of cultural appropriation
• The footwear resembles traditional Kolhapuri chappals with GI status
• Prada says designs are still in development and open to dialogue with India

Keep ReadingShow less
Anna Wintour

Wintour’s style of leadership earned her the nickname “Nuclear Wintour”

Getty Images

Anna Wintour steps down as editor of US Vogue after 37 years

Key points

  • Anna Wintour steps down as editor of US Vogue after 37 years
  • She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
  • Wintour transformed US Vogue into a global fashion authority
  • The 75-year-old has received numerous honours, including the Presidential Medal of Freedom

End of an era at US Vogue

Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.

The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.

Keep ReadingShow less
Nadiya Hussain

She also reassured her followers that “exciting” new projects are on the way

Getty Images

“I won’t always be grateful” says Nadiya Hussain after BBC axes her cookery show

Key points

  • Nadiya Hussain confirms BBC will not renew her cookery series
  • Bake Off winner challenges expectations to remain “grateful”
  • She says hard work and talent, not luck, brought her success
  • Celebrities, including Annie Lennox and Fearne Cotton, show support

BBC ends decade-long collaboration with Bake Off star

Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.

The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
M&S launches strawberries

M&S’s latest offering taps into both tradition and innovation

The Wire

M&S launches strawberries and cream sandwich ahead of Wimbledon

Summary

  • M&S unveils limited edition strawberries and cream sandwich for £2.80
  • Inspired by Japanese 'sweet sandos', it features Red Diamond strawberries and whipped cream cheese
  • Available in stores now, found in the savoury sandwich aisle
  • Launch coincides with Wimbledon and British strawberry season
  • Wimbledon increases strawberries and cream price for first time in 15 years

New summer sandwich from M&S

Marks & Spencer has launched a limited edition M&S strawberry sandwich, combining classic British summer flavours with a Japanese twist. Priced at £2.80, the strawberries and cream sandwich is available in M&S stores now.

The dessert-style sandwich features M&S’s exclusive Red Diamond strawberries, whipped cream cheese, and sweetened bread. Despite its sweet contents, the product is found in the savoury sandwich section of M&S Food halls.

Keep ReadingShow less